{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:44:20Z","timestamp":1793148260934,"version":"4.5.0"},"reference-count":78,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormal calcium metabolism in sarcoidosis patients can lead to hypercalcemia, hypercalciuria, and kidney stones. Hypercalcemia in sarcoidosis is usually due to increased activity of 1\u03b1-hydroxylase in macrophages of pulmonary granulomata, resulting in low levels of 25-hydroxyvitamin D and high levels of calcitriol. Vitamin D supplementation may be dangerous for some sarcoidosis patients and is recommended only for those with decreased 25-hydroxyvitamin D and reduced or normal calcitriol level. Diagnosis, treatment of osteoporosis, and maintenance of bone health are complex issues for sarcoidosis patients. An approach to diagnosis and treatment of bone fragility is presented.<\/jats:p>","DOI":"10.1055\/s-0040-1713009","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T22:35:42Z","timestamp":1597098942000},"page":"618-625","source":"Crossref","is-referenced-by-count":15,"title":["Balancing Altered Calcium Metabolism with Bone Health in Sarcoidosis"],"prefix":"10.1055","volume":"41","author":[{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Clinical Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"02","key":"ref1","first-page":"113","article-title":"Calcium and vitamin D metabolism in sarcoidosis","volume":"30","author":"R P Baughman","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref2","first-page":"209","article-title":"Clinical characteristics of sarcoidosis patients in the United States versus China","volume":"34","author":"Y Zhou","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000505653","article-title":"The role of urinary calcium and chitotriosidase in a cohort of chronic sarcoidosis patients","volume":"99","author":"P Cameli","year":"2020","journal-title":"Respiration"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5114\/reum.2018.80715","article-title":"Serum and urinary calcium level in Latvian patients with sarcoidosis","volume":"56","author":"I Ru\u017ea","year":"2018","journal-title":"Reumatologia"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11926-011-0170-1","article-title":"Bone health issues in sarcoidosis","volume":"13","author":"N J Sweiss","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00198-017-4115-z","article-title":"Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis","volume":"28","author":"O A Oshagbemi","year":"2017","journal-title":"Osteoporos Int"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00007611-200406000-00016","article-title":"Renal failure and hypercalcemia as initial manifestations of extrapulmonary sarcoidosis","volume":"97","author":"C Ponce","year":"2004","journal-title":"South Med J"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjms.2016.05.027","article-title":"Vitamin D supplementation: not so simple in sarcoidosis","volume":"352","author":"A Sodhi","year":"2016","journal-title":"Am J Med Sci"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"P J Tebben","year":"2016","journal-title":"Endocr Rev"},{"issue":"01","key":"ref11","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"M A Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"R P Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref13","first-page":"380","article-title":"Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences","volume":"34","author":"P Brito-Zer\u00f3n","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"01","key":"ref14","first-page":"34","article-title":"Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil","volume":"28","author":"S C Rodrigues","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1523-1755.2000.00202.x","article-title":"Identification of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression in macrophages","volume":"58","author":"T Monkawa","year":"2000","journal-title":"Kidney Int"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.161.4.755","article-title":"Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis","volume":"161","author":"J S Adams","year":"1985","journal-title":"J Exp Med"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000400","article-title":"Current concepts regarding calcium metabolism and bone health in sarcoidosis","volume":"23","author":"R P Baughman","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0002-9343(01)00724-0","article-title":"Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis","volume":"110","author":"N Inui","year":"2001","journal-title":"Am J Med"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.rmed.2009.12.004","article-title":"Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis","volume":"104","author":"D Kavathia","year":"2010","journal-title":"Respir Med"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/MCB.22.8.2777-2787.2002","article-title":"Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription","volume":"22","author":"M Vidal","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells","volume":"193","author":"J Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar4519","article-title":"Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients","volume":"16","author":"N Saidenberg-Kermanac'h","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/jbmr.2262","article-title":"Calcium and vitamin D in sarcoidosis: is supplementation safe?","volume":"29","author":"L S Kamphuis","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"02","key":"ref24","first-page":"607","article-title":"Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia","volume":"81","author":"K Nakayama","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1744-9987.12434","article-title":"Comparison of the Pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis population","volume":"20","author":"\u017d Ve\u010deri\u0107-Haler","year":"2016","journal-title":"Ther Apher Dial"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1210\/jc.2012-4197","article-title":"Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels","volume":"98","author":"V Lim","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/sarh.2002.31553","article-title":"Vertebral sarcoidosis: clinical and imaging findings","volume":"31","author":"I R\u00faa-Figueroa","year":"2002","journal-title":"Semin Arthritis Rheum"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00198-017-3962-y","article-title":"Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013","volume":"28","author":"P Ungprasert","year":"2017","journal-title":"Osteoporos Int"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00198-015-3426-1","article-title":"Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort","volume":"27","author":"S Bours","year":"2016","journal-title":"Osteoporos Int"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5606\/ArchRheumatol.2019.6883","article-title":"Bone mineral loss and fracture in sarcoidosis: a systematic review and meta-analysis","volume":"34","author":"W C Yong","year":"2018","journal-title":"Arch Rheumatol"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00198-014-2870-7","article-title":"Bone density is normal and does not change over 2 years in sarcoidosis","volume":"26","author":"M J Bolland","year":"2015","journal-title":"Osteoporos Int"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.semarthrit.2017.02.004","article-title":"Clinical characteristics of patients with bone sarcoidosis","volume":"47","author":"Y Zhou","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"01","key":"ref33","first-page":"29","article-title":"Bone loss in untreated longstanding sarcoidosis","volume":"8","author":"L Montemurro","year":"1991","journal-title":"Sarcoidosis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"N A Khan","year":"2017","journal-title":"Respir Med"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","article-title":"Effects of low-dose prednisone on bone metabolism","volume":"20","author":"F N Ton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","article-title":"Mechanisms of glucocorticoid-induced osteoporosis","volume":"15","author":"E Canalis","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00774-003-0448-0","article-title":"Bone mineral density in women with sarcoidosis","volume":"22","author":"S Sipahi","year":"2004","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"J M Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","article-title":"A pooled analysis of vitamin D dose requirements for fracture prevention","volume":"367","author":"H A Bischoff-Ferrari","year":"2012","journal-title":"N Engl J Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-012-2224-2","article-title":"Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study","volume":"24","author":"R L Prentice","year":"2013","journal-title":"Osteoporos Int"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.autrev.2003.10.001","article-title":"Sarcoidosis succumbs to antibiotics--implications for autoimmune disease","volume":"3","author":"T G Marshall","year":"2004","journal-title":"Autoimmun Rev"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jim-2016-000101","article-title":"Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis","volume":"64","author":"G Capolongo","year":"2016","journal-title":"J Investig Med"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"e003562","DOI":"10.1136\/bmjopen-2013-003562","article-title":"Randomised controlled trial of vitamin D supplementation in sarcoidosis","volume":"3","author":"M J Bolland","year":"2013","journal-title":"BMJ Open"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jbspin.2017.03.003","article-title":"Vitamin D supplementation in patients treated for sarcoidosis: controversy or consensus?","volume":"84","author":"N Saidenberg-Kermanac'h","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S0034-89102010000300011","article-title":"Risk factors for osteoporotic fractures and low bone density in pre and postmenopausal women","volume":"44","author":"M M Pinheiro","year":"2010","journal-title":"Rev Saude Publica"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194","author":"N E Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7861\/clinmedicine.14-2-187","article-title":"Osteoporosis and fracture risk in older people","volume":"14","author":"T Coughlan","year":"2014","journal-title":"Clin Med (Lond)"},{"issue":"08","key":"ref48","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"R P Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/aje\/kws145","article-title":"Reproductive and hormonal factors in relation to incidence of sarcoidosis in US Black women: the Black Women's Health Study","volume":"176","author":"Y C Cozier","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.rmed.2014.12.012","article-title":"Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan","volume":"109","author":"M Sawahata","year":"2015","journal-title":"Respir Med"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2298\/VSP1001013M","article-title":"Clinical and radiographic features of sarcoidosis in menopausal women--the impact on therapeutic approach and prognosis","volume":"67","author":"V R Miloikovi\u0107","year":"2010","journal-title":"Vojnosanit Pregl"},{"issue":"26","key":"ref52","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"L Buckley","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/ard.62.2.186","article-title":"Effect of low dose weekly methotrexate on bone mineral density and bone turnover","volume":"62","author":"S Patel","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"03","key":"ref54","first-page":"327","article-title":"Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate","volume":"18","author":"M Mazzantini","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0961203319841434","article-title":"Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy","volume":"28","author":"T Rolvien","year":"2019","journal-title":"Lupus"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/archderm.1996.03890260086013","article-title":"Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis","volume":"132","author":"I M Zonneveld","year":"1996","journal-title":"Arch Dermatol"},{"issue":"23","key":"ref57","doi-asserted-by":"crossref","first-page":"ijms20236085","DOI":"10.3390\/ijms20236085","article-title":"Azathioprine has a deleterious effect on the bone health of mice with DSS-induced inflammatory bowel disease","volume":"20","author":"S Morgan","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ref58","doi-asserted-by":"crossref","first-page":"e6374","DOI":"10.1590\/1414-431x20176374","article-title":"Bone mineral density and inflammatory bowel disease severity","volume":"50","author":"C A Lima","year":"2017","journal-title":"Braz J Med Biol Res"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.22691","article-title":"Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus","volume":"56","author":"S Compeyrot-Lacassagne","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","article-title":"Biologic therapies and bone loss in rheumatoid arthritis","volume":"28","author":"C AF Zerbini","year":"2017","journal-title":"Osteoporos Int"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00774-013-0535-9","article-title":"The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid","volume":"32","author":"T Okano","year":"2014","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"ref62","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical Practice Guideline Update From the American College of Physicians","volume":"166","author":"A Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1097\/BOT.0000000000001743","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"34","author":"R B Conley","year":"2020","journal-title":"J Orthop Trauma"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002239900352","article-title":"Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients","volume":"61","author":"S Gonnelli","year":"1997","journal-title":"Calcif Tissue Int"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000441-200301000-00001","article-title":"Glucocorticoid-induced osteoporosis in patients with sarcoidosis","volume":"325","author":"R A Adler","year":"2003","journal-title":"Am J Med Sci"},{"key":"ref66","first-page":"1841","article-title":"Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients","volume":"27","author":"R E Friedrich","year":"2007","journal-title":"Anticancer Res"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ger.12416","article-title":"Medication-related osteonecrosis of the jaw-like lesions in rodents: a comprehensive systematic review and meta-analysis","volume":"36","author":"S Kuroshima","year":"2019","journal-title":"Gerodontology"},{"issue":"10","key":"ref68","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"10","author":"N H Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41413-020-0088-1","article-title":"Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors","volume":"8","author":"J T Wan","year":"2020","journal-title":"Bone Res"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice","volume":"30","author":"R S de Molon","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"e0193846","DOI":"10.1371\/journal.pone.0193846","article-title":"The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial","volume":"13","author":"K Iseri","year":"2018","journal-title":"PLoS One"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2147\/DDDT.S148654","article-title":"Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"13","author":"Z A Yanbeiy","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"ref73","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"S Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"O Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"D L Kendler","year":"2018","journal-title":"Lancet"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis","volume":"40","author":"C L Liu","year":"2017","journal-title":"Clin Invest Med"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2011.05.031","article-title":"Vitamin D metabolism and activity in the parathyroid gland","volume":"347","author":"F Bienaim\u00e9","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jbspin.2015.11.007","article-title":"Teriparatide for osteoporosis in patients with sarcoidosis: report on risk-benefit ratio in four cases","volume":"83","author":"S Challal","year":"2016","journal-title":"Joint Bone Spine"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1713009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T22:38:05Z","timestamp":1597099085000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1713009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":78,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1713009","relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}